Recombinant Human CXCL8/IL-8 protein (Myc Tag, His Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
Myc Tag, His Tag
Activity
not tested
Cat no : Eg0152
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human CXCL8 protein Ser28-Ser99 (Accession# P10145) with a Myc tag and a His tag at the C-terminus. |
| GeneID | 3576 |
| Accession | P10145 |
| PredictedSize | 14 kDa |
| SDS-PAGE | 13-20 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Interleukin 8 (IL-8), also known as CXCL8, which is a member of the CXC chemokine family. This chemokine is secreted by a variety of cell types including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, and various tumor cell lines in response to inflammatory stimuli. IL-8 has two primary functions. It induces chemotaxis in target cells, primarily neutrophils but also other granulocytes, causing them to migrate toward the site of infection. IL-8 also induces phagocytosis once they have arrived. This gene is believed to play a role in the pathogenesis of bronchiolitis, a common respiratory tract disease caused by viral infection. IL-8 is also known to be a potent promoter of angiogenesis. IL-8 has been associated with tumor angiogenesis, metastasis, and poor prognosis in breast cancer. IL-8 may present a novel therapeutic target for estrogen driven breast carcinogenesis and tumor progression.
References:
1.Fu, Xuanrong et al. Front Immunol. 2023;14:1159061. 2.Cambier, Seppe et al. Cell Mol Immunol. 2023;20(3):217-251. 3.Shkundin, Anton, and Angelos Halaris. J Pers Med. 2024;14(5):488.